Pheton Holdings Ltd Sets Pricing for Initial Public Offering
Today marks an important milestone for Pheton Holdings Ltd as it has officially announced the offering price for its initial public offering (IPO). This healthcare solution provider is recognized for its innovative treatment planning systems specifically designed for brachytherapy and related services. The company intends to issue 2,250,000 Class A ordinary shares at a competitive price of $4.00 per share, targeting total gross proceeds of around $9 million, excluding underwriting discounts and other expenses.
Offering Details
Alongside the initial share issuance, Pheton has granted its underwriters a 45-day option to acquire an additional 337,500 Class A ordinary shares at the same public offering price, minus any applicable underwriting discounts. This option could potentially increase the funds generated from the IPO. Trading for these shares is expected to begin soon on the Nasdaq Capital Market under the ticker symbol "PTHL," with the anticipated closing date for the offering set for the following day, pending standard closing conditions.
Underwriters and Legal Advisors
The underwriting process is being conducted on a firm commitment basis, with CATHAY SECURITIES, INC. serving as the lead underwriter and representative. Dominari Securities LLC is acting as a co-underwriter. Legal matters are being addressed by Hunter Taubman Fischer & Li LLC, which is providing counsel to Pheton, while The Crone Law Group P.C. represents the underwriters.
About the Company
Pheton Holdings Ltd operates through its wholly owned subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd. The company was founded with the goal of improving healthcare solutions, particularly in the field of brachytherapy—a targeted radiation therapy essential for cancer treatment. Pheton's flagship product, the Treatment Planning System, focuses on the precise use of radioactive sources that work directly within the patient's body to eradicate cancer cells and reduce tumor size. This cutting-edge approach aims to set new standards of care across various tumor types, underscoring the company’s dedication to enhancing patient outcomes in oncology.
Information for Investors
Interested investors can find more detailed information about the Offering by reviewing documents filed with the U.S. Securities and Exchange Commission (SEC). It is recommended that potential investors carefully read the available prospectus and related documents as part of their investment evaluation process.
Contact for More Information
For any questions or additional information regarding the IPO, Pheton Holdings Ltd offers multiple communication channels. Investors can contact the company via email at ir@ftzy.com.cn.
Frequently Asked Questions
What is Pheton Holdings Ltd known for?
Pheton Holdings Ltd is known for its healthcare solutions, particularly in the development of treatment planning systems for brachytherapy used in cancer treatment.
How many shares is Pheton offering in its IPO?
The company is offering 2,250,000 Class A ordinary shares as part of its initial public offering.
What is the expected price range for the shares?
The shares are priced at $4.00 each, with an aim to raise total gross proceeds of $9 million, excluding underwriting fees.
When will trading begin for Pheton's shares?
Trading is expected to commence on the Nasdaq Capital Market shortly after the IPO concludes.
How can investors learn more about Pheton's IPO?
Investors can access the prospectus and other related SEC filings to gain comprehensive information about the IPO and the company's operations.
